LUCD Company Profile and Key Details

Lucid Diagnostics Inc. (NASDAQ:LUCD) closed at $0.78 USD, losing -$0.02 (-2.64%) from the previous close of $0.80. The stock is currently trading near its 52-week low $0.78 and $1.63. With a market capitalization of about $149.36 million, Lucid Diagnostics Inc. is classified as a micro-cap and shows market-like volatility (beta ~1.10). Key stats such as the average daily volume over the past year has been around 1.42 million shares, in line with its 52-week average. Headquartered in New York City, NY, Lucid Diagnostics Inc. operates in the Healthcare sector and the Medical - Devices industry. Led by CEO Lishan Aklog, the company employs approximately 82 people and listed since October 14, 2021. Lucid Diagnostics Inc. is a commercial-stage medical technology firm focused on diagnostic solutions.

Short-term trend indicators are bearishly aligned (SMA20 13.91%, SMA50 21.83%, SMA200 26.67%). The stock’s 14-day RSI is 68.8 (firm momentum), while the ATR of 0.08 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -18.33% below its high and over 54.82% above its low. Average 10-day trading volume of 1.24 million shares is below the 3-month average of 1.41 million, indicating normal recent market interest.

Lucid Diagnostics Inc. has 190.95 million shares outstanding. The public float is 140.76 million shares, elevated short interest at 7.87% of float. This equals 12.13 million shares. The short ratio is 8.1 days. Institutional investors hold 26.51% of the float. Insiders own 26.53%. PAVmed Inc. holds 27.93 million shares, Matheis Dennis has 1.03 million shares and Lapidus Stanley has 101.59 thousand shares. Over the past six months, insider transactions show net buying. They sold 0.00 shares across 0 transactions.

Lucid Diagnostics Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $3.72. This means the shares are trading below this model’s fair value.

Lucid Diagnostics Inc. generated EPS of -$0.90 over the past year. Five-year average earnings growth is -54.43%. The latest quarter delivered EPS of -$0.06. The next quarter is forecast at -$0.06. Next year's EPS is expected at $23.71. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 9 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $9.25 to $2.00. The high target offers 1085.9% upside. The low target suggests 156.41% downside. The mean target is $5.28. This offers 576.92% upside. Lucid Diagnostics Inc. earnings surprise history is a consistent trend of beating forecasts. The quarter that ended August 13, 2026, missed forecasts by 5.88%. The prior quarter beat by 240.0%. Over the last six quarters, Apple has recorded several small beats. These include 77.78% in May 14, 2025.

Lucid Diagnostics Inc. trades at a P/E ratio of -1.68, slightly below the S&P 500 average, with a price-to-sales ratio of 27.43 and a price-to-book ratio of 13.12 reflecting a rich premium to book value. The P/FCF stands at -3.17, also below market averages. Compared to sector medians, Lucid Diagnostics Inc. P/S is trading rich, and the P/B is far higher than peers, underscoring the brand and earnings power premium investors assign to the stock.

Lucid Diagnostics Inc. (NASDAQ:LUCD) shares are up 11.01% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Lucid Diagnostics Inc. trading at a premium to the broader market with a P/E of -1.68. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $4.53, suggesting 478.62% upside. Our AI forecast model points to short-term weakness (-15.7% over two weeks), a medium-term fall (-68.07% over three months), and a longer-term gain (1137.71% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Lucid Diagnostics Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -15.7%, with price expected at $0.66 by September 25, 2026, within a range of $0.62 to $0.69 3-Month Outlook: Projected fall of -68.07%, reaching $0.25 by December 10, 2026, with a range of $0.21 to $0.29. 1-Year Outlook: Projected gain of 1137.71%, with price at $9.69 by September 10, 2027, within a range of $6.22 to $12.20.